Patents by Inventor Arthur Fridman
Arthur Fridman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11854664Abstract: Embodiments of the present invention provide a computer-implemented system and method for generating and searching a database containing all of the potential substructures (e.g., metabolites) of a chosen complex molecule based on minimum cleavable units (MCUs) of the chosen complex molecule, wherein each record in the generated database suitably defines the molecular weight and physical arrangement of each substructure. Embodiments of the invention also provide a user interface and a search engine for searching the database based on a query molecular weight (or query molecular weight range) to identify all of the substructures having a total molecular weight matching the query molecular weight or range. Embodiments of the invention are also capable of transmitting to a display device operated by an end user a description and/or a graphical representation of every identified substructure of the chosen complex molecule.Type: GrantFiled: June 11, 2019Date of Patent: December 26, 2023Assignee: Merck Sharp & Dohme LLCInventors: Arthur Fridman, Ansuman Bagchi, Xiang Yu, Mark Cancilla
-
Publication number: 20230141153Abstract: The disclosure relates to stable RSV F proteins and immunogenic compositions containing the same, as well as methods of using the immunogenic compositions and compositions comprising the RSV F proteins.Type: ApplicationFiled: December 20, 2022Publication date: May 11, 2023Applicant: Merck Sharp & Dohme LLCInventors: Lan Zhang, Arthur Fridman, Eberhard Durr, Andrew Bett
-
Patent number: 11566051Abstract: The disclosure relates to stable RSV F proteins and immunogenic compositions containing the same, as well as methods of using the immunogenic compositions and compositions comprising the RSV F proteins.Type: GrantFiled: January 24, 2019Date of Patent: January 31, 2023Assignee: Merck Sharp & Dohme LLCInventors: Lan Zhang, Arthur Fridman, Eberhard Durr, Andrew Bett
-
Publication number: 20220280636Abstract: The disclosure relates to HSV glycoprotein E antigenic peptide constructs and HSV protein vaccines, as well as methods of using the vaccines and compositions comprising the vaccines. The present invention directed to immunogenic polypeptides of use for a vaccine against Herpes Simplex Vims (HSV). The polypeptides are glycoprotein E peptides that are mutated to reduce their binding to antibody Fc domain.Type: ApplicationFiled: July 14, 2020Publication date: September 8, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Arthur Fridman, Jennifer Dawn Galli, Dai Wang, Lan Zhang
-
Publication number: 20220034902Abstract: A method is described for identifying high affinity monoclonal antibody heavy and light chain pairs from high throughput screens of antibody producing cell libraries such as B-cell and hybridoma libraries. Specifically, the method relates to application of reversed immunocapture and high resolution tandem mass spectrometry for the identification of heavy and light chain pairs of binding antibodies obtained from high throughput screens of antibody producing cell libraries.Type: ApplicationFiled: December 6, 2019Publication date: February 3, 2022Applicant: Merck Sharp & Dohme Corp.Inventors: Eberhard Durr, Yaping Liu, Zhifeng Chen, Arthur Fridman
-
Publication number: 20210300971Abstract: The disclosure relates to stable RSV F proteins and immunogenic compositions containing the same, as well as methods of using the immunogenic compositions and compositions comprising the RSV F proteins.Type: ApplicationFiled: January 24, 2019Publication date: September 30, 2021Inventors: Lan Zhang, Arthur Fridman, Eberhard Durr, Andrew Bett
-
Publication number: 20210265024Abstract: Embodiments of the present invention provide a computer-implemented system and method for generating and searching a database containing all of the potential substructures (e.g., metabolites) of a chosen complex molecule based on minimum cleavable units (MCUs) of the chosen complex molecule, wherein each record in the generated database suitably defines the molecular weight and physical arrangement of each substructure. Embodiments of the invention also provide a user interface and a search engine for searching the database based on a query molecular weight (or query molecular weight range) to identify all of the substructures having a total molecular weight matching the query molecular weight or range. Embodiments of the invention are also capable of transmitting to a display device operated by an end user a description and/or a graphical representation of every identified substructure of the chosen complex molecule.Type: ApplicationFiled: June 11, 2019Publication date: August 26, 2021Applicant: Merck Sharp & Dohme Corp.Inventors: Arthur FRIDMAN, Ansuman BAGCHI, Xiang YU, Mark CANCILLA
-
Publication number: 20210257046Abstract: Embodiments of the present invention avoid the processing problems associated with using conventional computer systems for identifying and characterizing all of the substructures (e.g., metabolites) of large complex molecules by using a defined minimum cleavable unit (MCU) and an MCU graph for a chosen molecule, as well as a “cut vertex” in the MCU graph for the chosen molecule. The system splits the MCU graph of the chosen molecule at the specified cut vertex to produce two separate MCU graph components (i.e., a first MCU subgraph and a second MCU subgraph) of the chosen molecule, and generates and traverses a first line graph component and a second line graph component, respectively, for the two MCU subgraph components with a graph traversing algorithm to generate and store in memory a first database of substructures and molecular weights for the first component, and a second database of substructures and molecular weights for the second line graph component.Type: ApplicationFiled: June 11, 2019Publication date: August 19, 2021Applicant: Merck Sharp & Dohme Corp.Inventors: Arthur FRIDMAN, Ansuman BAGCHI, Xiang YU, Mark CANCILLA
-
Publication number: 20190314486Abstract: The disclosure relates to influenza virus hemagglutinin protein and DNA vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.Type: ApplicationFiled: October 18, 2017Publication date: October 17, 2019Applicant: Merck Sharp & Dohme Corp.Inventors: Jessica Anne Flynn, Lan Zhang, Kerim Babaoglu, Arthur Fridman, David Nickle
-
Patent number: 9447403Abstract: The present invention relates to peptides of the enolase protein from Staphylococcus aureus as well as nucleic acid and nucleic acid sequence homologs encoding the peptides. The present invention also relates to a composition, particularly a S. aureus vaccine, comprising one or more of the enolase peptides described herein or a fragment, derivative or variant thereof capable of generating an immune response that induces a protective antibody response or opsonophagocytic activity of human neutrophils for S. aureus. The present invention also encompasses methods of treating and/or reducing the likelihood of a Staphylococcus infection by administering a composition of the invention.Type: GrantFiled: October 3, 2013Date of Patent: September 20, 2016Assignee: Merck Sharp & Dohme Corp.Inventors: Tessie B. McNeely, Leslie Cope, Sharon Smith, Amita Joshi, Irene Pak, Arthur Fridman
-
Publication number: 20140030287Abstract: The present invention relates to peptides of the enolase protein from Staphylococcus aureus as well as nucleic acid and nucleic acid sequence homologues encoding the peptides. The present invention also relates to a composition, particularly a S. aureus vaccine, comprising one or more of the enolase peptides described herein or a fragment, derivative or variant thereof capable of generating an immune response that induces a protective antibody response or opsonophagocytic activity of human neutrophils for S. aureus. The present invention also encompasses methods of treating and/or reducing the likelihood of a Staphylococcus infection by administering a composition of the invention.Type: ApplicationFiled: October 3, 2013Publication date: January 30, 2014Inventors: TESSIE B. MCNEELY, LESLIE COPE, SHARON SMITH, AMITA JOSHI, IRENE PAK, ARTHUR FRIDMAN
-
Publication number: 20110182926Abstract: The present invention provides minigenes suitable as a prophylactic or therapeutic vaccine against conditions such as cancer, infectious diseases or autoimmune diseases, and pharmaceutical compositions comprising the minigene. The minigenes of the present invention comprise (a) a human tissue plasminogen signal peptide; (b) at least one T-cell epitope; and (c) an E. coli heat labile enterotoxin B subunit; wherein the at least one T-cell epitope is linked to the rest of the minigene, and to any other epitopes, by furin sensitive linkers. In some embodiments of the invention, the minigene comprises T-cell epitopes from one or more of CEA, her-2/neu and hTERT. Also provided herein are immunogenic peptide epitopes of CEA, her-2/neu and hTERT, as well as immunogenic peptide analogs, and pharmaceutical compositions and vaccines comprising one or more of said peptides and analogs for prophylaxis and/or treatment of cancer or other disorder.Type: ApplicationFiled: August 7, 2009Publication date: July 28, 2011Inventors: Nicola La Monica, Elisa Scarselli, Gennaro Ciliberto, Luigi Aurisicchio, Arthur Fridman, Ansuman Bagchi
-
Patent number: 7756644Abstract: Methodology for the automated selection and/or optimization of T-cell epitopes is disclosed. The invention provides a data processing system which utilizes sequence-based statistical pattern recognition to compute an epitope selection matrix based on the informational content of epitopes known to bind to a particular major histocompatibility class I allele. The resulting Bayes-corrected scoring matrix is used to predict the relative binding affinities of candidate T-cell epitopes derived from immunologically relevant antigens of self or foreign origin. One aspect of the invention describes an analytical method for identification of modifications in known or predicted T-cell epitopes that confer upon the epitopes the ability to elicit stronger cellular immune response due to more efficient processing and/or presentation to T-cells.Type: GrantFiled: May 8, 2006Date of Patent: July 13, 2010Assignee: Merck & Co., Inc.Inventors: Arthur Fridman, Ansuman Bagchi, Wendy Bailey
-
Publication number: 20060257944Abstract: Methodology for the automated selection and/or optimization of T-cell epitopes is disclosed. The invention provides a data processing system which utilizes sequence-based statistical pattern recognition to compute an epitope selection matrix based on the informational content of epitopes known to bind to a particular major histocompatibility class I allele. The resulting Bayes-corrected scoring matrix is used to predict the relative binding affinities of candidate T-cell epitopes derived from immunologically relevant antigens of self or foreign origin. One aspect of the invention describes an analytical method for identification of modifications in known or predicted T-cell epitopes that confer upon the epitopes the ability to elicit stronger cellular immune response due to more efficient processing and/or presentation to T-cells.Type: ApplicationFiled: May 8, 2006Publication date: November 16, 2006Inventors: Arthur Fridman, Ansuman Bagchi, Wendy Bailey